Nivolumab (Opdivo)

DRUG3 trials

Sponsors

Bayer, New York Medical College

Conditions

Anaplastic Large Cell Lymphoma, ALK-PositiveColorectal CancerSolid Tumors

Phase 2

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

CompletedNCT04126733

BayerColorectal Cancer

Start: 2019-10-14End: 2022-03-28Updated: 2023-07-18

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

CompletedNCT04704154

BayerSolid Tumors

Start: 2021-02-03End: 2024-03-29Updated: 2025-04-18

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

RecruitingNCT07013565

New York Medical CollegeAnaplastic Large Cell Lymphoma, ALK-Positive

Start: 2025-08-07End: 2030-07-01Target: 20Updated: 2026-05-20

Related Papers

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

The Oncologist2025-06-01

CTIM-32. A PARALLEL COHORT PHASE 2 STUDY OF REGORAFENIB PLUS NIVOLUMAB FOR RECURRENT OR METASTATIC SOLID TUMORS: RESULTS IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) OR ANAPLASTIC ASTROCYTOMA (AA)

Neuro-Oncology2023-11-012 citations

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.

2023-04-0671 citations

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Journal of Clinical Oncology2022-01-193 citations

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Journal of Clinical Oncology2021-05-2072 citations